J. Kahn

发表

A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group.

T. Merigan, J. Kahn, S. Lagakos, 1992, The New England journal of medicine.

Cellular Immune Responses and Viral Diversity in Individuals Treated during Acute and Early HIV-1 Infection

E. Rosenberg, M. Altfeld, B. Walker, 2001, The Journal of experimental medicine.

Acute human immunodeficiency virus type 1 infection.

B. Walker, J. Kahn, B D Walker, 1998, The New England journal of medicine.

The safety and pharmacokinetics of GLQ223 in subjects with AIDS and AIDS-related complex: a phase I study.

J. Kahn, P. Volberding, J. Lifson, 1990, AIDS.

Evaluation of HIV-1 immunogen, an immunologic modifier, administered to patients infected with HIV having 300 to 549 x 10(6)/L CD4 cell counts: A randomized controlled trial.

J. Kahn, S. Lagakos, K. Mayer, 2000, JAMA.

Predicting the transmission of drug-resistant HIV: comparing theory with data.

J. Kahn, S. Blower, A. Aschenbach, 2003, The Lancet. Infectious diseases.

Cryotherapy for Cutaneous Kaposi's Sarcoma (KS) Associated with Acquired Immune Deficiency Syndrome (AIDS): A Phase II Trial

J. Kahn, P. Volberding, J. Tappero, 1991, Journal of acquired immune deficiency syndromes.

Phase I/II Trial of the Pharmacokinetics, Safety, and Antiretroviral Activity of Tenofovir Disoproxil Fumarate in Human Immunodeficiency Virus-Infected Adults

J. Kahn, P. Barditch-Crovo, A. Collier, 2001, Antimicrobial Agents and Chemotherapy.

Preventing hepatitis A and hepatitis B virus infections among men who have sex with men.

J. Kahn, 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: the San Francisco PEP Study.

J. Kahn, Jeffrey N. Martin, M. Chesney, 2001, The Journal of infectious diseases.

Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers.

J. Kahn, K. Steimer, C. Dekker, 1994, The Journal of infectious diseases.

Treatment of AIDS-related Kaposi's sarcoma.

J. Kahn, P. Volberding, D. Northfelt, 1991, Hematology/Oncology Clinics of North America.

Intralesional recombinant tumor necrosis factor-alpha for AIDS-associated Kaposi's sarcoma: a randomized, double-blind trial.

J. Kahn, P. Volberding, J. Ziegler, 1989, Journal of acquired immune deficiency syndromes.

Weekly doxorubicin in the treatment of patients with AIDS-related Kaposi's sarcoma. AIDS Clinical Trials Group.

J. Kahn, P. Volberding, M. Fischl, 1993, Journal of acquired immune deficiency syndromes.

Oral and Intravenous Zidovudine Pharmacokinetics: The Effect of Granulocyte‐Macrophage Colony Stimulating Factor

J. Kahn, F. Aweeka, D. Cutler, 1995, Journal of clinical pharmacology.

Clinical and virologic effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma: results of a randomized trial.

J. Kahn, P. Volberding, J. Mills, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 1 study of recombinant human CD4-immunoglobulin G therapy of patients with AIDS and AIDS-related complex

T. L. Hodges, J. Kahn, P. Volberding, 1991, Antimicrobial Agents and Chemotherapy.

Use of postexposure prophylaxis against HIV infection following sexual exposure does not lead to increases in high-risk behavior

J. Kahn, R. Kohn, Jeffrey N. Martin, 2004, AIDS.

The safety and pharmacokinetics of recombinant soluble CD4 (rCD4) in subjects with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase 1 study.

T. L. Hodges, J. Kahn, J. Groopman, 1990, Annals of internal medicine.

HIV-1 p17 synthetic peptide vaccine HGP-30: induction of immune response in human subjects and preliminary evidence of protection against HIV challenge in SCID mice.

J. Kahn, B. Gazzard, M. Youle, 1995, Cellular and molecular biology.

Safety, activity, and pharmacokinetics of GLQ223 in patients with AIDS and AIDS-related complex

J. Kahn, J. Lifson, A. Bostrom, 1994, Antimicrobial Agents and Chemotherapy.

From the cell to the community: AIDS research in California. The University of California Universitywide AIDS Research Program annual meeting, February 2000.

R. Haubrich, J. Kahn, M. Goldsmith, 2000, The Western journal of medicine.

New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes.

G A Satten, M P Busch, J. Kahn, 1998, JAMA.

AIDS-associated non-Hodgkin's lymphoma in San Francisco.

J. Kahn, P. Volberding, J. Ziegler, 1989, JAMA.

Safety, Pharmacokinetics, and Antiretroviral Activity of Intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a Novel Anti-Human Immunodeficiency Virus (HIV) Therapy, in HIV-Infected Adults

Steven G. Deeks, James F. Rooney, J. Kahn, 1998, Antimicrobial Agents and Chemotherapy.

HIV-1 protease inhibitors. A review for clinicians.

J. Kahn, Mark A. Smith, S. Deeks, 1997 .

Comparative Effectiveness of Fish Oil Versus Fenofibrate, Gemfibrozil, and Atorvastatin on Lowering Triglyceride Levels Among HIV-Infected Patients in Routine Clinical Care

J. Kahn, J. Willig, M. Mugavero, 2013, Journal of acquired immune deficiency syndromes.

Prototype trial design for rapid dose selection of antiretroviral drugs: an example using emtricitabine (Coviracil).

J. Kahn, D. Shepp, D. Mildvan, 2001, The Journal of antimicrobial chemotherapy.

Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial.

M. Wulfsohn, J. Kahn, S. Lagakos, 1999, JAMA.

A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A Study Team.

M A Fischl, J. Phair, M. Hirsch, 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Cohort profile: the Centers for AIDS Research Network of Integrated Clinical Systems.

Richard D Moore, R. Haubrich, M. Lederman, 2008, International journal of epidemiology.

Risk behavior for HIV infection in participants in preventive HIV vaccine trials: a cautionary note.

J. Kahn, M. Chesney, M A Chesney, 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Patterns of opportunistic infections in patients with HIV infection.

G Molenberghs, G. Molenberghs, J. Kahn, 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

The clinical use of didanosine.

J. Kahn, 1996, Advances in experimental medicine and biology.

Efficacy and Safety of Adefovir Dipivoxil With Antiretroviral Therapy

Michael I. Miller, M. Wulfsohn, J. Kahn, 2017 .

Use of laboratory tests and clinical symptoms for identification of primary HIV infection

Michael P Busch, E. Rosenberg, J. Kahn, 2002, AIDS.

Seroconversion following nonoccupational postexposure prophylaxis against HIV.

J. Kahn, Jeffrey N. Martin, F. Hecht, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Cost-effectiveness of postexposure prophylaxis after sexual or injection-drug exposure to human immunodeficiency virus.

J. Kahn, Jeffrey N. Martin, M. Katz, 2004, Archives of internal medicine.

Anti-human immunodeficiency virus therapeutics: now and the future.

J. Kahn, 1992, Seminars in liver disease.

Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load.

Peter Hunt, Lea Liu, J. Kahn, 2004, Blood.

Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors.

J. Kahn, B. Branson, C. Petropoulos, 1998, The New England journal of medicine.

Neurological reactions in HIV‐infected patients treated with trichosanthin

J. Kahn, H. Vinters, D. Bredesen, 1993, Neuropathology and applied neurobiology.

Zidovudine Compared With Didanosine in Patients With Advanced HIV Type I Infection and Little or No Previous Experience With Zidovudine

K. K. Lai, D. Katzenstein, M. Hirsch, 1995 .

Low-dose chemotherapy with central nervous system prophylaxis and zidovudine maintenance in AIDS-related lymphoma. A prospective multi-institutional trial.

J. Kahn, J. Bennett, A. Levine, 1991, JAMA.

Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (ACTG) 116B/117 Study Team. ACTG Virology Committee Resistance and HIV-1 RNA Working Groups.

J. Kahn, D. Richman, C. Crumpacker, 1996, The Journal of infectious diseases.

Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: A randomized controlled trial.

J. Kahn, W. Leong, R. Dewar, 2000, JAMA.

The effect of a "universal antiretroviral therapy" recommendation on HIV RNA levels among HIV-infected patients entering care with a CD4 count greater than 500/μL in a public health setting.

C. B. Hare, J. Kahn, D. Havlir, 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection

Todd M. Allen, E. Rosenberg, M. Altfeld, 2003, AIDS (London).

Reduction in CD8+ cell noncytotoxic anti-HIV activity in individuals receiving highly active antiretroviral therapy during primary infection.

J. Kahn, F. Hecht, J. Levy, 2001, Proceedings of the National Academy of Sciences of the United States of America.

HIV RNA testing in the context of nonoccupational postexposure prophylaxis.

J. Kahn, Jeffrey N. Martin, T. Elbeik, 2004, The Journal of infectious diseases.

Primary HIV infection

C. B. Hare, J. Kahn, C. Hare, 2004, Current infectious disease reports.

Higher CD4+ T cell counts associated with low viral pol replication capacity among treatment-naive adults in early HIV-1 infection.

M. Segal, J. Kahn, T. Wrin, 2004, The Journal of infectious diseases.

Longitudinal analysis of T-cell receptor gene use by CD8(+) T cells in early human immunodeficiency virus infection in patients receiving highly active antiretroviral therapy.

E. Vittinghoff, J. Kahn, F. Hecht, 2001, Blood.

Time trends in primary HIV-1 drug resistance among recently infected persons.

J. Kahn, M. Warmerdam, C. Petropoulos, 2002, JAMA.

Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy

J. Kahn, D. Richman, C. Crumpacker, 1996 .

Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy. AIDS Clinical Trials Group Protocol 116A/116B/117 Team.

J. Kahn, D. Richman, C. Crumpacker, 1996, The Journal of infectious diseases.

Predicting the unpredictable: Transmission of drug-resistant HIV

H. Gershengorn, J. Kahn, S. Blower, 2001, Nature Medicine.

Absolute or total lymphocyte count as a marker for the CD4 T lymphocyte criterion for initiating antiretroviral therapy.

J. Kahn, F. Hecht, M. Jacobson, 2003, AIDS.

Clinical, immunologic, and virologic observations related to human immunodeficiency virus (HIV) type 1 infection in a volunteer in an HIV-1 vaccine clinical trial.

J. Kahn, K. Steimer, T. Elbeik, 1995, The Journal of infectious diseases.

Antibody and cellular immune responses in breakthrough infection subjects after HIV type 1 glycoprotein 120 vaccination.

J. Kahn, E. Collisson, J. Levy, 1999, AIDS research and human retroviruses.

Interleukin-2 therapy restores CD8 cell non-cytotoxic anti-HIV responses in primary infection subjects receiving HAART

J. Kahn, F. Hecht, J. Levy, 2004, AIDS.

Predicting the unpredictable: Transmission of drug-resistant HIV

H. Gershengorn, J. Kahn, S. Blower, 2003, Nature Medicine.

Cost-effectiveness of HIV postexposure prophylaxis following sexual or injection drug exposure in 96 metropolitan areas in the United States

J. Kahn, Jeffrey N. Martin, M. Katz, 2004, AIDS.

Uric acid and didanosine compliance in AIDS clinical trials: an analysis of AIDS Clinical Trials Group protocols 116A and 116B/117.

J. Kahn, S. Liou, D. Richardson, 1993, Journal of acquired immune deficiency syndromes.

Discovery and clinical development of HIV-1 protease inhibitors.

J. Kahn, J. Huff, Joel R. Huff, 2001, Advances in protein chemistry.

Postexposure prophylaxis for human immunodeficiency virus infection after sexual or injection drug use exposure: identification and characterization of the source of exposure.

J. Kahn, Jeffrey N. Martin, R. Grant, 2001, The Journal of infectious diseases.

The antiretroviral rollout and drug-resistant HIV in Africa: insights from empirical data and theoretical models.

Erin N. Bodine, Erin Bodine, Willi McFarland, 2005, AIDS.

Predictors of survival in HIV-infected persons with 50 or fewer CD4 cells/mm3.

J. Phair, J. Kahn, C. Spino, 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

AIDS-associated Kaposi's sarcoma.

J. Kahn, D. Northfelt, J. Kahn, 1990, AIDS clinical review.

Booster immunization of HIV-1 negative volunteers with HGP-30 vaccine induces protection against HIV-1 virus challenge in SCID mice.

J. Kahn, H. Gendelman, J. Talmadge, 1999, Vaccine.

Weekly oral etoposide in patients with Kaposi's sarcoma associated with human immunodeficiency virus infection: a phase I multicenter trial of the AIDS Clinical Trials Group.

J. Kahn, M. Feldstein, J. Bennett, 1995, Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology.

Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. AIDS Clinical Trials Group 116B/117 Study Team and the Virology Committee Resistance Working Group.

J. Kahn, D. Richman, C. Crumpacker, 1995, The Journal of infectious diseases.

Phase 1 study of combination therapy with L-697,661 and zidovudine

R. Schooley, J. Phair, J. Kahn, 1996 .

Quantifying the treatment efficacy of reverse transcriptase inhibitors: new analyses of clinical data based on within-host modeling

Romulus Breban, Sally Blower, J. Kahn, 2009, BMC public health.